Sign in

You're signed outSign in or to get full access.

Joe Phillips and Jeff

Research Analyst at Not Disclosed / Biovantage

No verifiable information is available regarding Joe Phillips and Jeff as analysts at Not Disclosed / Biovantage, including details about their titles, coverage universe, performance metrics, career timeline, or professional credentials. Despite an extensive search, neither individual's LinkedIn profile nor any third-party industry profiles provide evidence of their roles, achievements, or analyst performance rankings at this firm. There are no publicly accessible records confirming their employment at Biovantage or their registration with regulatory bodies such as FINRA. As such, a comprehensive professional profile cannot be constructed at this time.

Joe Phillips and Jeff's questions to RECURSION PHARMACEUTICALS (RXRX) leadership

Question · FY 2024

Joe Phillips and Jeff from Biovantage asked for updates on the timing and commercialization path for REC-994 in CCM, questioning the efficacy signals and the rationale for continued development.

Answer

CEO Christopher Gibson pushed back on the characterization of the trial being 'negative on efficacy.' He explained it was a 'signal-finding' study not powered for statistical significance, which successfully identified encouraging trends in lesion reduction via MRI and functional improvement via the modified Rankin score. He stated these signals warrant further exploration in a larger trial and that the company will provide clearer plans after discussions with the FDA and analysis of long-term extension data.

Ask follow-up questions

Fintool

Fintool can predict RECURSION PHARMACEUTICALS logo RXRX's earnings beat/miss a week before the call